Biopharma giants Amgen Inc. and Eli
Lilly earlier this month announced an antibody manufacturing collaboration for potential COVID-19 treatments, in an effort to scale up production for multiple treatments still in development.
The collaboration between Thousand Oaks-based Amgen and Lilly, headquartered in Indianapolis, will significantly boost global supply capacity for Lilly’s COVID treatments, the companies said.
...

Join our Membership to get the full story.


Are you a current Member? Sign In